~A Boy Always Young~

2015年8月7日 星期五

Three comdined pituitary function test



test for growth hormone deficiency
TRH test, LH-RH test, Insulin tolerance test

1. midnight NPO
2. On 20 號 medicut + 3 way, 接N/S(500ml) keep open (勿接IV lock)
3. Bed rest
4. 備血糖機及2amp 50% GW(for hypoglycemia with loss of conscious)
5. 8AM抽血
    ==> GH,  IGF-1,  TSH,  free T4,  LH,  FSH, PRL
           testosterone, E2,  ACTH, Cortisol,  plasma sugar
6. HRI        0.2 u/kg  iv push
    TRH       0.5 mg  iv push  30秒
    LH-RH   100 ug (0.1mg) iv push
7. 8點開始test後,第15' 30' 45' 60' 90' 120'分鐘時
   用血糖機測finger sugar
   同時要抽血測GH,  TSH,  LH,  FSH,  plasma sugar, Cortisol
8. check CBC/DC, Iron, TIBC, Ferritin, PLT, BUN,  Cr,  Na,  K
9. CXR
10. 請家屬幫忙準備含糖食物或飲料(果汁, 豆奶或糖果等)

1. TRH test==>注射TRH30'後,TSH應上升6以上,或大於2倍baseline值
2. LH-RH test==>LH在30' or 60'後上升4~6倍。FSH可能會上升一倍。
3. Insulin tolerance test==>GH在45'~60'後應至少上升7ng/mL(通常都10~20)。Cortisol通常會上升一倍。
read more

Test for primary aldosteronism



#  hypertension and hypokalemia are controlled
#  avoiding spironolactone and eplerenone

A. Oral sodium loading
<<Oral sodium loading test>>
1. 抽Aldosterone and Renin activity
2. 請病人每天吃鹽6 g,吃兩天
3. 第三天開始留24-hr尿,檢測urine aldosterone, Na/K, Cr.
4. Urine aldosterone excretion >12 to 14 mcg/24 hrs-->確診
5. Urinary excretion of sodium >200 mEq/day-->adequet sample

B. Intravenous sodium loading test (ABAYSALIN)
<<Saline infusion test>>
1. 請病人平躺
2. stat 抽Aldosterone and Renin activity before N/S hydration
3. N/S 2L run 4hr
4. 抽 Aldosterone and renin activity after N/S hydration
5. On EKG monitor, check BP and HR Q15 mins during test
6. If patient complained of SOB, chest discomfort, headache, etc...
    ==> please call Dr to see if the test should be stoped.
7. test 後PAC >10 ng/dL --> 確診,PAC <5 ng/dL --> 排除

C. Captopril challenge test
<<Captopril challenge test>>
1. 請病人至少維持坐立或站立一小時再開始test,直到結束
2. Captopril 25–50 mg PO
3. 服藥後1hr, 2hr各抽一次PRA, Aldosterone, Cortisol
4. Aldosterone >15ng/dl --> 確診

The use of the fludrocortisone suppression test is limited
The captopril suppression test is less standardized alternative if sodium loading is
contraindicated as in heart or renal failure.
read more

2015年8月6日 星期四

Hypercalacemia


ü  低鈣àPTH釋放àbone resorption, calcium reabsorption in the kidney, and increased production of activated vitamin D in the kidneyà升鈣
ü  PTH-mediated bone resorption is mediated by the RANKRANK ligand-OPG system.
ü  Hypercalcemia is an elevation of free, ionized calcium in the serum.
ü  Levels <12 mg/dL are asymptomatic; levels >15 mg/dL may cause severe symptoms. Rapidly progressing hypercalcemia is more likely to be symptomatic.
ü  The two most common causes of hypercalcemia: primary hyperparathyroidism and malignancy.
ü  原因:
²  increased bone resorption
Ø  PTH: 80%adenoma,還有hyperplasia, carcinoma, MEN
Ø  CKD: 因為鈣低、Vit-D缺乏à2nd hyperparathyroidismàtertiary
Ø  Malignancy:
u  PTHrP: primarily in squamous cell carcinomas, can also be seen in cancers of the kidney, ovary, and bladder. It is a frequent complication in lymphomas associated with HTLV-1.
u  Cancers with extensive skeletal metastases (multiple myeloma, breast cancer): release of cytokines (TGF-b, IL-1, IL-6, and macrophage inflammatory protein-1α) leads to osteoclast differentiation and inhibition of osteoblasts.
u  Ectopic: carcinomas of the lung, thymus, ovary, and undifferentiated neuroendocrine tumors
u  lymphoma and some ovarian dysgerminomas: increasing 1-hydroxylation of vitamin Dà higher 1,25-OH-vitamin D àincreased calcium absorption
Ø  Thyrotoxicosis: increased bone turnover
Ø  Excessive intake of vitamin A (>50,000 to 100,000 IU daily): IL-6增加
Ø  Prolonged immobilization
²  Vitamin D-dependent mechanisms
Ø  Chronic ingestion of more than 50,000 to 100,000 IU/day of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3)
Ø  Excessive or accidental ingestion of 1,25(OH)2D (calcitriol)àshould resolve within days.
Ø  Granulomatous: conversion of 25(OH)D to 1,25(OH)2D by macrophages
²  Milk–alkali syndrome: ingestion of milk or calcium carbonate, in the treatment of dyspepsia or osteoporosis. à associated with metabolic alkalosis and renal insufficiency
²  Other hormonal mechanisms
²  Drugs:
Ø  Thiazide: mild and transient (1 to 2 weeks)
Ø  Lithium: shifts the set point for calcium
Ø  Additional medications: estrogens, growth hormones, ganciclovir, omeprazole, 8-Cl-cAMP chemotherapy, manganese toxicity, foscarnet, hepatitis B vaccination, theophylline
²  Familial hypocalcuric hypercalcemia: 無症狀,heterozygous loss-of-function mutation in the calcium sensing receptoràincreased set point for calcium homeostasisàmildly elevated PTH, hypocalcuria, and hypermagnesemia
²  Miscellaneous other causes: adrenal insufficiency, pheochromocytoma, pancreas islet cell tumors, rhabdomyolysis恢復期, aluminum intoxication(diminished osteoblastic activity and reduced calcium incorporation into the skeleton)

ü  S/S: Neuropsychiatric symptoms, arrhythmia, constipation, polyuria and polydipsia, nephrolithiasis, Skeletal manifestations (osteoporosis or osteitis fibrosa cystica)
ü  先抽iPTH
²  à驗尿鈣: 如果FeCa<1%FHH>1%primary hyperpara

²  à猜惡性、驗Vit-D: 如果1,25OH高猜lymphomagranulomatous,如果25OH高猜Vit-D中毒。如果Vit-D正常猜雜七雜八的東西。
read more

2015年7月24日 星期五

SIADH



ü  ADHà 腎的V2à distal tubule and collecting ductàfree water retention and dilutional hyponatremiaà elevated urine osmolality in the setting of a low plasma osmolality

Essential diagnostic criteria:
ü  Plasma osmolality <275 mOsm/kg
ü  Urine osmolality >100 mOsm/kg and urine Na >20 to 40mEq/L
ü  Euvolemia
ü  Normal renal, adrenal, and thyroid function tests
ü  No recent use of diuretic agents

Euvolemic hypotonic hyponatremia:
ü  The most common cause of euvolemic hypotonic hyponatremia is SIADH.
ü  Characterized by low to normal total body sodium and normal to elevated total body water.
²  Hypothyroidismà dysregulation of ADH release or clearance, effects on vascular tone, cardiac output, and renal blood flow
²  Adrenal insufficiencyà caused by the loss of negative feedback on ADH secretion
²  Primary polydipsia
²  Potomania
²  Thiazide diuretics
²  Reset osmostat syndromeà shift in the set-point for ADH
²  Nephrogenic syndrome of inappropriate antidiuresisà mutations in the renal vasopressin V2 receptor causing increased water resorption,表現同SIADHADH測不到
ü  SIADH is usually self-limited, and the primary management strategy is to correct the underlying etiology.
ü  Loop diureticsà增加free water 排出、讓腎對ADH反應下降àenhance the effect of solute loading
ü  Demeclocycline acts on the renal collecting tubules to diminish responsiveness to ADH. The major side effect is nephrotoxicity.
ü  Vasopressin receptor antagonists exert their activity on renal V2 receptors resulting in a selective water diuresis without affecting sodium excretion

read more

2015年7月21日 星期二

Subclinical hyperthyroidism



原因:同甲亢
ü   Autoimmune thyroid disease
ü   Autonomous thyroid tissue
ü   TSH-mediated hyperthyroidism
ü   Human chorionic gonadotropin-mediated hyperthyroidism
ü   Thyroiditis
ü   Ectopic hyperthyroidism
會影響:
ü   The skeleton (bone resorption) and the cardiovascular system (increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina) are the major target tissues adversely affected.
ü   Subclinical hyperthyroidism may also be associated with an increased risk of dementia.
評估:病史、用藥、PE
ü   Patients on suppressive levothyroxine therapyàTSH低是目標
ü   Patients on T4 for the treatment of hypothyroidismà不可以讓TSH太低
ü   女人要問有沒有懷孕,停經後或有骨鬆風險,可做骨密度檢查作為決定要不要治療的參考依據。
ü   沒吃T4patientspersistently subnormal TSH values,如考慮藥治療,we obtain a radioactive iodine uptake and scan to help determine the etiology. 如有不只一處increased uptake, this could account for the low serum TSH. 如果沒有吸收,the etiology of subclinical hyperthyroidism may be thyroiditis or recent iodine exposure.
ü   Most patients with thyroiditis require no treatment.
ü   Patients at high risk for complications(>65 years of age, with risk factors for cardiac arrhythmias, and postmenopausal women with or at risk for osteoporosis)
èIf TSH <0.1 mU/L, we treat the underlying cause of subclinical hyperthyroidism.
èIf TSH is 0.1 to 0.5 mU/L, we suggest treatment if there is underlying cardiovascular disease or if the bone density is low.
ü   Patients at low risk for complications
èIf TSH <0.1 mU/L, we treat the underlying cause if the patient has symptoms suggestive of hyperthyroidism and/or if a thyroid radionuclide scan shows 不只一處吸收。
èf TSH is 0.1 to 0.5 mU/L, 觀察就好

ü   In observed patients, we measure TSH, free T4, and T3 every six months
read more

2015年6月3日 星期三

adrenal incidentaloma



1. Cushing==>
     check ACTH/Cortisol(08:00 and 23:00)
           urine cortisol
2. Pheochromocytoma==>
     check 24-hour urinary metanephrines and catecholamines
3. Aldosteronomas==>
     check Na/K, Renin activity and aldosterone

Please also check 24-hr urine Na/K/Cr at the same time
read more

2015年4月9日 星期四

高血脂健保給付



全民健康保險降三酸甘油酯藥物給付規定
CAD or DM: TG≧200 且 TC/HDL-C>5 或 HDL-C<40
No CAD nor DM: 3-6 個月非藥物治療


全民健康保險降膽固醇藥物給付規定
CAD or DM: TC>160 or LSLS>100
危險因子:
1.高血壓
2. 男性≧45 歲,女性≧55 歲或停經者
3. 有早發性冠心病家族史(男性≦55 歲,女性≦65 歲)
4. HDL-C<40mg/dL
5. 吸菸(因吸菸而符合起步治療準則之個案,若未戒菸而要求藥物治療,應以自費治療)。

2 factors: TC>200 or LDL >130
1 factor: TC>240 or LDL > 160
0 factor: LDL > 190
read more